Indegene’s share price soared after Axis Direct initiated coverage with a ‘buy’ recommendation, suggesting an 18% upside. The company’s blend of biopharma expertise and AI solutions positions it well for future growth, as per the brokerage firm.
Read more at the source
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and credits belong to the original authors and publishers.